Immunosuppression: trends and tolerance?

[1]  J. Wagner,et al.  Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  O. Martinez,et al.  Differential expression and functions of microRNAs in liver transplantation and potential use as non-invasive biomarkers. , 2013, Transplant immunology.

[3]  Qizhi Tang,et al.  Regulatory T-cell therapy in transplantation: moving to the clinic. , 2013, Cold Spring Harbor perspectives in medicine.

[4]  A. Sánchez‐Fueyo.  Tolerance profiles and immunosuppression , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  D. Roelen,et al.  Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients , 2013, Hepatology.

[6]  L. Rostaing,et al.  Long‐Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long‐Term Extension of the BENEFIT Study , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  C. Pan,et al.  Tolerance and chimerism and allogeneic bone marrow/stem cell transplantation in liver transplantation. , 2013, World journal of gastroenterology.

[8]  J. Rakela,et al.  New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database , 2013, Journal of transplantation.

[9]  J. Friedewald,et al.  Genomic biomarkers correlate with HLA-identical renal transplant tolerance. , 2013, Journal of the American Society of Nephrology : JASN.

[10]  Z. Wang,et al.  Plasma MicroRNA, a Potential Biomarker for Acute Rejection After Liver Transplantation , 2013, Transplantation.

[11]  J. Markmann,et al.  Mechanisms of regulatory T cell counter-regulation by innate immunity. , 2013, Transplantation reviews.

[12]  G. Tisone,et al.  The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10‐year follow‐up , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  S. Uemoto,et al.  Frequent hepatocyte chimerism in long-term human liver allografts independent of graft outcome. , 2013, Transplant immunology.

[14]  M. Abecassis,et al.  Tolerance Induction in HLA Disparate Living Donor Kidney Transplantation by Donor Stem Cell Infusion: Durable Chimerism Predicts Outcome , 2013, Transplantation.

[15]  G. Klintmalm,et al.  Sirolimus and Cardiovascular Disease Risk in Liver Transplantation , 2013, Transplantation.

[16]  S. Uemoto,et al.  Intragraft V&dgr;1 &ggr;&dgr; T Cells With a Unique T-Cell Receptor Are Closely Associated With Pediatric Semiallogeneic Liver Transplant Tolerance , 2013, Transplantation.

[17]  P. Parrilla,et al.  What do we know about the clinical impact of complete withdrawal of immunosuppression in liver transplantation? , 2012, Transplantation proceedings.

[18]  M. Sarwal,et al.  A Common Peripheral Blood Gene Set for Diagnosis of Operational Tolerance in Pediatric and Adult Liver Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  J. Lozano,et al.  Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. , 2012, Journal of the American Society of Nephrology : JASN.

[20]  A. Nijagal,et al.  Maternal microchimerism in patients with biliary atresia , 2012, Chimerism.

[21]  P. Zhu,et al.  Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  M. Abecassis,et al.  Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation , 2012, Science Translational Medicine.

[23]  P. Archdeacon,et al.  Summary of the US FDA Approval of Belatacept , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  G. Kazemier,et al.  Hepatocyte‐derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[25]  A. Humar,et al.  Sirolimus Conversion Regimen Versus Continued Calcineurin Inhibitors in Liver Allograft Recipients: A Randomized Trial , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  R. Alloway,et al.  Immunosuppression, Generic Drugs and the FDA , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  G. McCaughan,et al.  Tolerance in liver transplantation. , 2012, Best practice & research. Clinical gastroenterology.

[28]  J. Rakela,et al.  Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation , 2012, Journal of transplantation.

[29]  P. Rosenthal,et al.  Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. , 2012, JAMA.

[30]  D. Swinkels,et al.  Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. , 2012, The Journal of clinical investigation.

[31]  Y. Li,et al.  Factors affecting operational tolerance after pediatric living‐donor liver transplantation: impact of early post‐transplant events and HLA match * , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[32]  M. Scian,et al.  MicroRNA Profiles in Allograft Tissues and Paired Urines Associate With Chronic Allograft Dysfunction With IF/TA , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  R. Montgomery,et al.  Mobilization of Host Stem Cells Enables Long‐Term Liver Transplant Acceptance in a Strongly Rejecting Rat Strain Combination , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  C. Götherström.  Immunomodulation by mesenchymal stem cells and clinical experience , 2011 .

[35]  W. Gwinner,et al.  Urinary miR‐210 as a Mediator of Acute T‐Cell Mediated Rejection in Renal Allograft Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[36]  P. Dutta,et al.  Correlation between post transplant maternal microchimerism and tolerance across MHC barriers in mice , 2011, Chimerism.

[37]  J. Wagner,et al.  Generation and Large‐Scale Expansion of Human Inducible Regulatory T Cells That Suppress Graft‐Versus‐Host Disease , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  Bruce R. Blazar,et al.  Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity , 2011, Science Translational Medicine.

[39]  J. Markmann,et al.  Generation of Adaptive Regulatory T Cells by Alloantigen Is Required for Some But Not All Transplant Tolerance Protocols , 2011, Transplantation.

[40]  F. Fändrich.  Tolerance in clinical transplantation: progress, challenge or just a dream? , 2011, Langenbeck's Archives of Surgery.

[41]  S. Uemoto,et al.  The Generation of Donor-Specific CD4+CD25++CD45RA+ Naive Regulatory T Cells in Operationally Tolerant Patients After Pediatric Living-Donor Liver Transplantation , 2010, Transplantation.

[42]  J. Moon,et al.  Long-Term Follow-Up of 23 Operational Tolerant Liver Transplant Recipients , 2010, Transplantation.

[43]  R. Goto,et al.  Ex Vivo–Expanded Human Regulatory T Cells Prevent the Rejection of Skin Allografts in a Humanized Mouse Model , 2010, Transplantation.

[44]  A. Sánchez‐Fueyo.  Identification of tolerant recipients following liver transplantation. , 2010, International immunopharmacology.

[45]  V. Ng,et al.  Glomerular Filtration Rate Following Pediatric Liver Transplantation—The SPLIT Experience , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[46]  M. Masetti,et al.  Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  K. Watt,et al.  Metabolic syndrome and liver transplantation: a review and guide to management. , 2010, Journal of hepatology.

[48]  Graham M Lord,et al.  Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. , 2010, The Journal of clinical investigation.

[49]  W. Kremers,et al.  Evolution of Causes and Risk Factors for Mortality Post‐Liver Transplant: Results of the NIDDK Long‐Term Follow‐Up Study , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[50]  Paul L. Martin,et al.  Risk Factors for New-Onset Diabetes Mellitus in Adult Liver Transplant Recipients, an Analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing Database , 2010, Transplantation.

[51]  G. Mazariegos,et al.  Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. , 2010, Human immunology.

[52]  J. Heimbach,et al.  Antibody‐Based Immunosuppression Following Liver Transplantation: The Plot Thickens , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[53]  A. Kapke,et al.  The Influence of Induction Therapy on Graft and Patient Survival in Patients with and without Hepatitis C after Liver Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[54]  S. Uemoto,et al.  Induced tolerance to rat liver allografts involves the apoptosis of intragraft T cells and the generation of CD4+CD25+FoxP3+ T regulatory cells , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[55]  U. Neumann,et al.  Safety of mycophenolate mofetil monotherapy in patients after liver transplantation. , 2009, Annals of transplantation.

[56]  G. Gores,et al.  Long-term probability of and mortality from de novo malignancy after liver transplantation. , 2009, Gastroenterology.

[57]  J. Markmann,et al.  GITR Blockade Facilitates Treg Mediated Allograft Survival , 2009, Transplantation.

[58]  R. D'Agostino,et al.  Trajectories of Entering the Metabolic Syndrome: The Framingham Heart Study , 2009, Circulation.

[59]  A. Demetris.  Evolution of hepatitis C virus in liver allografts , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[60]  O. Guckelberger.  Long‐term medical comorbidities and their management: Hypertension/cardiovascular disease , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[61]  A. Nademanee,et al.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  G. Sgourakis,et al.  Corticosteroid‐free immunosuppression in liver transplantation: a meta‐analysis and meta‐regression of outcomes , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[63]  Dong-Wook Kim,et al.  Full donor chimerism using stem-cell transplantation for tolerance induction in the human leukocyte antigen-matched liver transplant setting. , 2009, Transplantation.

[64]  A. Burroughs,et al.  Azathioprine in Liver Transplantation: A Reevaluation of Its Use and a Comparison with Mycophenolate Mofetil , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[65]  A. Nademanee,et al.  Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.

[66]  J. Martínez-López,et al.  Long‐term follow‐up of donor chimerism and tolerance after human liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[67]  P. Parrilla,et al.  Immunosuppression withdrawal improves long‐term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients , 2009, Clinical transplantation.

[68]  G. McCaughan,et al.  Molecular and Cellular Aspects of Hepatitis C Virus Reinfection After Liver Transplantation: How the Early Phase Impacts on Outcomes , 2009, Transplantation.

[69]  Darshana Dadhania,et al.  MicroRNA expression profiles predictive of human renal allograft status , 2009, Proceedings of the National Academy of Sciences.

[70]  D. Campani,et al.  Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[71]  J. Gugenheim,et al.  Mycophenolate Mofetil Monotherapy for Severe Side Effects of Calcineurin Inhibitors Following Liver Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[72]  J. Neuberger,et al.  Delayed Introduction of Reduced‐Dose Tacrolimus, and Renal Function in Liver Transplantation: The ‘ReSpECT' Study , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[73]  Thomas Becker,et al.  Patient Outcomes in Two Steroid-Free Regimens Using Tacrolimus Monotherapy After Daclizumab Induction and Tacrolimus With Mycophenolate Mofetil in Liver Transplantation , 2008, Transplantation.

[74]  Y. Li,et al.  The Presence of Foxp3 Expressing T Cells Within Grafts of Tolerant Human Liver Transplant Recipients , 2008, Transplantation.

[75]  V. Ng,et al.  Outcomes of 5-Year Survivors of Pediatric Liver Transplantation: Report on 461 Children From a North American Multicenter Registry , 2008, Pediatrics.

[76]  P. Parrilla,et al.  FoxP3 in Peripheral Blood Is Associated With Operational Tolerance in Liver Transplant Patients During Immunosuppression Withdrawal , 2008, Transplantation.

[77]  G. Marchesini,et al.  Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[78]  G. Tisone,et al.  The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. , 2008, Transplant immunology.

[79]  B. Ranchin,et al.  Renal Function in Pediatric Liver Transplantation: A Long-Term Follow-Up Study , 2008, Transplantation.

[80]  Shu-sen Zheng,et al.  Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. , 2008, Hepatobiliary & pancreatic diseases international : HBPD INT.

[81]  M. Schnitzler,et al.  A Prospective, Randomized, Double-Blinded Comparison of Thymoglobulin Versus Atgam for Induction Immunosuppressive Therapy: 10-Year Results , 2008, Transplantation.

[82]  E. Gane.  The natural history of recurrent hepatitis C and what influences this , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[83]  S. Feng.  Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both? , 2008, Current opinion in organ transplantation.

[84]  J. Torras,et al.  Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. , 2008, Journal of the American Society of Nephrology : JASN.

[85]  Charles M. Miller,et al.  The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[86]  B. Pannier,et al.  Recent advances in metabolic syndrome and cardiovascular disease. , 2008, Archives of cardiovascular diseases.

[87]  J. L. Pozo.  Update and actual trends on bacterial infections following liver transplantation. , 2008 .

[88]  P. Parrilla,et al.  Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. , 2008, The Journal of clinical investigation.

[89]  A. Thomson,et al.  New Insights into Mechanisms of Spontaneous Liver Transplant Tolerance: The Role of Foxp3‐Expressing CD25+CD4+ Regulatory T Cells , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[90]  A. Krasinskas,et al.  Histologic Abnormalities are Common in Protocol Liver Allograft Biopsies From Patients With Normal Liver Function Tests , 2008, The American journal of surgical pathology.

[91]  Zuojin Liu,et al.  Role of Kupffer cells in the induction of tolerance of orthotopic liver transplantation in rats , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[92]  L. Rostaing,et al.  Predictive Factors for Posttransplant Diabetes Mellitus Within One-Year of Liver Transplantation , 2008, Transplantation.

[93]  P. Thuluvath,et al.  Steroid avoidance in liver transplantation: Meta‐analysis and meta‐regression of randomized trials , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[94]  S. McDiarmid,et al.  Risk Factors for Rejection and Infection in Pediatric Liver Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[95]  V. Sharma,et al.  HLA-mismatched renal transplantation without maintenance immunosuppression. , 2008, The New England journal of medicine.

[96]  G. Alexander,et al.  A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)‐based to sirolimus‐based immunosuppression in liver transplant recipients with impaired renal function , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[97]  D. Samuel,et al.  Risk factors for hepatitis C recurrence after liver transplantation , 2007, Journal of viral hepatitis.

[98]  N. Terrault,et al.  Management of hepatitis B in liver transplant recipients , 2007, Journal of viral hepatitis.

[99]  D. Samuel,et al.  Long‐term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[100]  N. Assy,et al.  Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid , 2007, Transplantation.

[101]  G. Klintmalm,et al.  Calcineurin inhibitor‐sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity , 2007, Clinical transplantation.

[102]  J. Neuberger,et al.  Reducing the Risks of Cardiovascular Disease in Liver Allograft Recipients , 2007, Transplantation.

[103]  P. Morel,et al.  Conversion to sirolimus‐based immunosuppression in maintenance liver transplantation patients , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[104]  M. Ramoni,et al.  Multiparameter Immune Profiling of Operational Tolerance in Liver Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[105]  G. Mazariegos,et al.  Clinical tolerance following liver transplantation: long term results and future prospects. , 2007, Transplant immunology.

[106]  U. Tannuri,et al.  Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: Experience of a single center , 2007, Pediatric transplantation.

[107]  G. Tisone,et al.  Operational tolerance in clinical liver transplantation: emerging developments. , 2007, Transplant immunology.

[108]  Y. Li,et al.  Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. , 2007, Transplant immunology.

[109]  J. Dumortier,et al.  Risk factors for new‐onset diabetes mellitus following liver transplantation and impact of hepatitis c infection : An observational multicenter study , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[110]  J. Moon,et al.  Negative Impact of New-Onset Diabetes Mellitus on Patient and Graft Survival After Liver Transplantation: Long-Term Follow Up , 2006, Transplantation.

[111]  R. Colvin,et al.  Myeloma Responses and Tolerance Following Combined Kidney and Nonmyeloablative Marrow Transplantation: In Vivo and In Vitro Analyses , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[112]  F. Reinholt,et al.  Liver biopsy interpretation for causes of late liver allograft dysfunction , 2006, Hepatology.

[113]  A. Sánchez‐Fueyo,et al.  An Appraisal of Tolerance in Liver Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[114]  S. Saab,et al.  Prevalence and Risk Factors for Diabetes Mellitus in Moderate Term Survivors of Liver Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[115]  R. Malthaner,et al.  Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta‐Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[116]  S. Hübscher,et al.  Progressive histological damage in liver allografts following pediatric liver transplantation , 2006, Hepatology.

[117]  J. Trotter,et al.  Immunosuppression: Evolution in Practice and Trends, 1994–2004 , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[118]  G. Tisone,et al.  Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. , 2006, Journal of hepatology.

[119]  C. June,et al.  Clinical application of expanded CD4+25+ cells. , 2006, Seminars in immunology.

[120]  N. Terrault,et al.  Management of Hepatitis C in Liver Transplant Recipients , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[121]  J. Kwekkeboom,et al.  Low circulating regulatory T‐cell levels after acute rejection in liver transplantation , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[122]  Richard W Morris,et al.  Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. , 2005, Archives of internal medicine.

[123]  Chao-Long Chen,et al.  The renal‐sparing efficacy of basiliximab in adult living donor liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[124]  J. Bradley,et al.  Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. , 2005, Critical reviews in oncology/hematology.

[125]  P. Clavien,et al.  Mycophenolate Mofetil for Renal Dysfunction in Liver Transplant Recipients on Cyclosporine or Tacrolimus: Randomized, Prospective, Multicenter Pilot Study Results , 2005, Transplantation.

[126]  J. Tuomilehto,et al.  The metabolic syndrome and cardiovascular risk. , 2005, Current diabetes reviews.

[127]  N. Heaton,et al.  Long-term outcome of immunosuppression withdrawal after liver transplantation. , 2005, Transplantation proceedings.

[128]  X. Zheng,et al.  CTLA4 Engagement is Required for Induction of Murine Liver Transplant Spontaneous Tolerance † , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[129]  J. Moon,et al.  The Role of Donor Bone Marrow Infusions in Withdrawal of Immunosuppression in Adult Liver Allotransplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[130]  K. Le Blanc,et al.  Mesenchymal stem cells: progress toward promise. , 2005, Cytotherapy.

[131]  Yoshimasa Tanaka,et al.  Analyses of Peripheral Blood Mononuclear Cells in Operational Tolerance After Pediatric Living Donor Liver Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[132]  C. June,et al.  CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. , 2004, Blood.

[133]  T. Nomura,et al.  Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. , 2004, International immunology.

[134]  Gustavo Boldrini,et al.  Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: Changes in the immune responses , 2004, Pediatric transplantation.

[135]  R. Colvin,et al.  CD154 Blockade for Induction of Mixed Chimerism and Prolonged Renal Allograft Survival in Nonhuman Primates , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[136]  G. Loss,et al.  Tolerance: Is It Worth the Risk? , 2005, Transplantation.

[137]  M. Schnitzler,et al.  Five-Year Follow Up of Thymoglobulin Versus ATGAM Induction in Adult Renal Transplantation , 2004, Transplantation.

[138]  G. Mazariegos,et al.  Dendritic Cell Subset Ratio in Tolerant, Weaning and Non‐Tolerant Liver Recipients Is Not Affected by Extent of Immunosuppression , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[139]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[140]  A. Fietta,et al.  Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome , 2004, Transplantation.

[141]  G. Klintmalm,et al.  Chronic renal failure after transplantation of a nonrenal organ. , 2003, The New England journal of medicine.

[142]  T. Strom,et al.  The balance of deletion and regulation in allograft tolerance , 2003, Immunological reviews.

[143]  M. Charlton.  Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[144]  J. Lake.  The role of immunosuppression in recurrence of hepatitis C , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[145]  S. Tueche.  Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. , 2003, Transplantation proceedings.

[146]  J. Yélamos,et al.  Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression1 , 2003, Transplantation.

[147]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[148]  D. Harlan,et al.  Studies Investigating Pretransplant Donor-Specific Blood Transfusion, Rapamycin, and the CD154-Specific Antibody IDEC-131 in a Nonhuman Primate Model of Skin Allotransplantation1 , 2003, The Journal of Immunology.

[149]  J. Fung,et al.  The pathogenesis and management of influenza virus infection in organ transplant recipients , 2002, Transplant infectious disease : an official journal of the Transplantation Society.

[150]  F. Delmonico,et al.  Induction Of Kidney Allograft Tolerance After Transient Lymphohematopoietic Chimerism In Patients With Multiple Myeloma And End-Stage Renal Disease1 , 2002, Transplantation.

[151]  J. Berlin,et al.  The association between hepatitis C infection and survival after orthotopic liver transplantation. , 2002, Gastroenterology.

[152]  G. Klintmalm,et al.  End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. , 2001, Transplantation.

[153]  T. Starzl,et al.  Transplantation tolerance from a historical perspective , 2001, Nature Reviews Immunology.

[154]  T. Starzl,et al.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow‐up of 6 years , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[155]  K. Dohi,et al.  Establishment of chimerism in donor liver with recipient-type bone marrow cells prior to liver transplantation produces marked suppression of allograft rejection in rats , 1998 .

[156]  B. Portmann,et al.  Defining the outcome of immunosuppression withdrawal after liver transplantation , 1998, Hepatology.

[157]  R. Colvin,et al.  Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. , 1997, Transplantation.

[158]  R. Colvin,et al.  Mixed chimerism and transplantation tolerance induced by a nonlethal preparative regimen in cynomolgus monkeys. , 1997, Transplantation proceedings.

[159]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[160]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[161]  H. Schlitt,et al.  Long-term chimerism in liver transplantation: no evidence for immunological relevance but requirement for graft persistence. , 1995, Transplantation proceedings.

[162]  R. Colvin,et al.  Mixed Allogeneic Chimerism And Renal Allograft Tolerance In Cynomolgus Monkeys , 1995, Transplantation.

[163]  L. A. Magna,et al.  Prospective analysis between the therapy of immunosuppressive medication and allogeneic microchimerism after liver transplantation. , 2009, Transplant immunology.

[164]  吉冨 摩美,et al.  Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation , 2009 .

[165]  B. Thiers.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2008 .

[166]  J. L. Del Pozo.  Update and actual trends on bacterial infections following liver transplantation. , 2008, World journal of gastroenterology.

[167]  B. Thiers.  Cancer Incidence Before and After Kidney Transplantation , 2007 .

[168]  K. Wood,et al.  The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. , 2005, Transplantation proceedings.

[169]  A. Kirk.  Transplantation tolerance: a look at the nonhuman primate literature in the light of modern tolerance theories. , 1999, Critical reviews in immunology.